Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim given EU backing for hypertension drug

Boehringer Ingelheim given EU backing for hypertension drug

27th July 2010

Boehringer Ingelheim has been granted a recommendation for European regulatory approval of a new pill-based treatment for hypertension.

The European Committee for Medicinal Products for Human Use has given a positive opinion on the company’s application for Twynsta, which combines telmisartan and amlodipine to treat adult patients suffering from the heart condition.

This approval has been granted on the back of three recent clinical trials, which demonstrated the drug’s efficacy when compared to its respective monotherapy options.

It will be indicated for patients who have either proven unresponsive to amlodipine, or as a replacement therapy for those already using telmisartan and amlodipine in separate tablet forms.

Professor Klaus Dugi, corporate senior vice-president for medicine at Boehringer Ingelheim, said: “We are pleased that, following a final decision from the European Medicines Agency, Twynsta will provide physicians with a valuable new treatment option for hypertensive patients.”

Last week, Boehringer Ingelheim published new clinical data from a study of its HIV drug Viramune, demonstrating its efficacy in a new once-daily indication.ADNFCR-8000103-ID-800006002-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.